Target Binding Site Detail
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T97719 | Target Info | |||
| Target Name | HUMAN bruton tyrosine kinase (BTK) | ||||
| Synonyms | Bruton's tyrosine kinase; Bruton tyrosine kinase; BPK; B-cell progenitor kinase; B cell progenitor kinase; Agammaglobulinemia tyrosine kinase; Agammaglobulinaemia tyrosine kinase; AGMX1 | ||||
| Gene Name | BTK | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Ligand General Information | Top | ||||
|---|---|---|---|---|---|
| Ligand Name | 4-[8-amino-3-[(2S)-1-[4-(dimethylamino)butanoyl]pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(1,3-thiazol-2-yl)benzamide | Ligand Info | |||
| Canonical SMILES | CN(C)CCCC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=NC=CS5 | ||||
| InChI | 1S/C26H30N8O2S/c1-32(2)13-4-6-20(35)33-14-3-5-19(33)24-30-21(22-23(27)28-11-15-34(22)24)17-7-9-18(10-8-17)25(36)31-26-29-12-16-37-26/h7-12,15-16,19H,3-6,13-14H2,1-2H3,(H2,27,28)(H,29,31,36)/t19-/m0/s1 | ||||
| InChIKey | HUXVNVAKNWKLJM-IBGZPJMESA-N | ||||
| PubChem Compound ID | 137348408 | ||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| PDB ID: 5FBN BTK kinase domain with inhibitor 1 | ||||||
| Method | X-ray diffraction | Resolution | 1.80 Å | Mutation | No | [1] |
| PDB Sequence |
WEIDPKDLTF
404 LKELGTGQFG414 VVKYGKWRGQ424 YDVAIKMIKE434 GSMSEDEFIE444 EAKVMMNLSH 454 EKLVQLYGVC464 TKQRPIFIIT474 EYMANGCLLN484 YLREMRHRFQ494 TQQLLEMCKD 504 VCEAMEYLES514 KQFLHRDLAA524 RNCLVNDQGV534 VKVSDFGLSR544 YVLDSKFPVR 562 WSPPEVLMYS572 KFSSKSDIWA582 FGVLMWEIYS592 LGKMPYERFT602 NSETAEHIAQ 612 GLRLYRPHLA622 SEKVYTIMYS632 CWHEKADERP642 TFKILLSNIL652 DVMDEE |
|||||
|
|
||||||
| PDB ID: 5FBO BTK-inhibitor co-structure | ||||||
| Method | X-ray diffraction | Resolution | 1.89 Å | Mutation | No | [1] |
| PDB Sequence |
YGSWEIDPKD
401 LTFLKELGTG411 QFGVVKYGKW421 RGQYDVAIKM431 IKEGSMSEDE441 FIEEAKVMMN 451 LSHEKLVQLY461 GVCTKQRPIF471 IITEYMANGC481 LLNYLREMRH491 RFQTQQLLEM 501 CKDVCEAMEY511 LESKQFLHRD521 LAARNCLVND531 QGVVKVSDFG541 LSSKFPVRWS 564 PPEVLMYSKF574 SSKSDIWAFG584 VLMWEIYSLG594 KMPYERFTNS604 ETAEHIAQGL 614 RLYRPHLASE624 KVYTIMYSCW634 HEKADERPTF644 KILLSNILDV654 MDEES |
|||||
|
|
||||||
| PDB ID: 6X3O Co-structure of BTK kinase domain with L-005191930 inhibitor | ||||||
| Method | X-ray diffraction | Resolution | 1.90 Å | Mutation | No | [2] |
| PDB Sequence |
WEIDPKDLTF
404 LKELGTGQFG414 VVKYGKWRGQ424 YDVAIKMIKE434 GSMSEDEFIE444 EAKVMMNLSH 454 EKLVQLYGVC464 TKQRPIFIIT474 EYMANGCLLN484 YLREMRHRFQ494 TQQLLEMCKD 504 VCEAMEYLES514 KQFLHRDLAA524 RNCLVNDQGV534 VKVSDFGLSR544 YVLDDEYTSS 554 VGSKFPVRWS564 PPEVLMYSKF574 SSKSDIWAFG584 VLMWEIYSLG594 KMPYERFTNS 604 ETAEHIAQGL614 RLYRPHLASE624 KVYTIMYSCW634 HEKADERPTF644 KILLSNILDV 654 MDEES
|
|||||
|
|
||||||
| PDB ID: 6X3N Co-structure of BTK kinase domain with L-005085737 inhibitor | ||||||
| Method | X-ray diffraction | Resolution | 1.95 Å | Mutation | No | [2] |
| PDB Sequence |
YGSWEIDPKD
401 LTFLKELGTG411 QFGVVKYGKW421 RGQYDVAIKM431 IKEGSMSEDE441 FIEEAKVMMN 451 LSHEKLVQLY461 GVCTKQRPIF471 IITEYMANGC481 LLNYLREMRH491 RFQTQQLLEM 501 CKDVCEAMEY511 LESKQFLHRD521 LAARNCLVND531 QGVVKVSDFG541 LSKFPVRWSP 565 PEVLMYSKFS575 SKSDIWAFGV585 LMWEIYSLGK595 MPYERFTNSE605 TAEHIAQGLR 615 LYRPHLASEK625 VYTIMYSCWH635 EKADERPTFK645 ILLSNILDVM655 DEES |
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .5WE or .5WE2 or .5WE3 or :35WE;style chemicals stick;color identity;select .A:394 or .A:395 or .A:396 or .A:397 or .A:421 or .A:425 or .A:427 or .A:453 or .A:459 or .A:460 or .A:461 or .A:462 or .A:473; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis. ACS Med Chem Lett. 2015 Dec 19;7(2):198-203. | ||||
| REF 2 | Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes. Bioorg Med Chem Lett. 2020 Sep 1;30(17):127390. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.